Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 696 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis, Chronic Clear all

Conditions: Chronic Hepatitis b, Viremia
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Liver Disease
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatocellular Carcinoma, Hepatitis B, Chronic
Interventions: One time blood draw; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Hepatitis C
Interventions: interferon alfa-2b, peginterferon alfa-2b, ribavirin, USP, external drug infusion pump; Drug · Device
Lead sponsor: Medtronic Corporate Technologies and New Ventures; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hepatitis b Virus, Hepatitis B
Interventions: HepB mAb19, Sterile Saline; Biological · Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: New York, New York

Conditions: Hepatitis C
Interventions: Sho-saiko-to; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis c
Interventions: pioglitazone (Actos), atorvastatin (Lipitor); Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C, Chronic
Interventions: GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 37
States / cities: Tucson, Arizona • Anaheim, California • Beverly Hills, California + 30 more

Conditions: Chronic Hepatitis C
Interventions: modified directly observed therapy (mDOT), unobserved dosing, Motivational Interviewing-based counseling; Other
Lead sponsor: Phillip Coffin, MD, MIA; Government
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 25
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 18 more

Conditions: Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions: ABT-450, ABT-072, Ribavirin, Ritonavir; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • San Antonio, Texas + 1 more

Conditions: Hepatitis C
Interventions: Pegylated Interferon Lambda, Ribasphere, Daclatasvir; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic HCV
Interventions: Quality of Life Therapy, Supportive Therapy; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 21 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: End-Stage Renal Disease, Hepatitis C
Interventions: Zepatier, Ribavirin, Sofosbuvir; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Viral Hepatitis
Interventions: Tobevibart, Elebsiran; Drug
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 13
States / cities: Chandler, Arizona • Los Angeles, California • Redwood City, California + 8 more

Conditions: Chronic Hepatitis C
Interventions: Sofosbuvir/Velpatasvir/Voxilaprevir; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HCV Infection
Interventions: GS-5885, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 13
States / cities: Anaheim, California • Cypress, California • National City, California + 10 more

Conditions: Hepatitis C, Chronic
Interventions: GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 54
States / cities: Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL/VOX, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C
Interventions: Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C
Interventions: Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin, Daclatasvir, Telaprevir; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 8
States / cities: Long Beach, California • Marietta, Georgia • New York, New York + 5 more

Conditions: Hepatitis C, Chronic Hepatitis C
Interventions: Miravirsen sodium, Telaprevir; Drug
Lead sponsor: Santaris Pharma A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Hepatitis D
Interventions: Lonafarnib, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C, Chronic
Interventions: Not listed
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 6,625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 162
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 102 more

Search by objective public record fields.

Adaptability of an Undetectable = Untransmissible Model for HBV

The Physiology of Fatigue in Patients With Chronic Liver Disease

Biologic Basis of Liver Cancer From Chronic Hepatitis B

Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C

HepB mAb19 in Individuals With Chronic Hepatitis B Infection

SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study

Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation

Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects

Lonafarnib for Chronic Hepatitis D

Gilead Sustained Virologic Response (SVR) Registry